Clinical trial · Observational
Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System
Observational Study of Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The VERO® SBRT System radiation machine had water damage and could not be repaired.
Summary
Brief summary (as posted)
Stereotactic Body Radiotherapy (SBRT) delivers an ablative dose of radiation to tumours, with high precision. This technique offers an alternative to surgery for lung lesions. The UZ Brussel of the VUB developed with the support of the Hercules foundation (grant for heavy research infrastructure) in collaboration with Brainlab AG a breathing-synchronized radiation technique on the VERO SBRT system, where the radiation beam follows the moving target (dynamic tumour tracking). The implantation of a marker in the tumour is thereby mandatory for its visualization but excluding patients with poor pulmonary function. Therefore Brainlab® recently released an update of the VERO SBRT system that allows "Markerless Tracking". This markerless technique is currently being implemented at the Radiotherapy Department of UZ Brussel for lung lesions. Hence we plan an observational study that will document the outcome of and feasibility for patients with lung lesions treated with markerless tracking on the VERO SBRT system at the Radiotherapy Department in UZ Brussel.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer Metastatic | — | UNRESOLVED | — |
| Lung Cancer, Nonsmall Cell | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
| Lung Cancer Stage IV | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Lung Diseases | — | UNRESOLVED | — |
| Stereotactic Body Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Standard radiotherapy treatment | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Markerless tracking
- description
- * Gross tumor volume for MLT (GTV\_MLT): lesion delineated on stable exhale phase of the 4DCT. * Planning target volume for MLT (PTV\_MLT): GTV + 8 mm isotropic expansion
- interventionNames
- Radiation: Standard radiotherapy treatment
- label
- ITV approach
- description
- * Gross tumor volume (GTV): lesion delineated on the ten phases of the 4DCT. * Internal target volume (ITV): propagate all GTV on stable exhale phase of the 4DCT. * Planning target volume for ITV (PTV\_ITV): ITV + 5 mm isotropic expansion
- interventionNames
- Radiation: Standard radiotherapy treatment
- label
- Markerbased tracking
- description
- * Gross tumor volume for tracking (GTV\_Track): lesion delineated on stable exhale phase of the 4DCT. * Planning target volume for tracking (PTV\_Track): GTV + 5 mm isotropic expansion
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Primary NSCLC patients, stage T1-2bN0M0 (TNM 8th edition) 2. Oligometastatic patients with ≤ 3 lung metastases; SBRT as a primary treatment or as a consolidative treatment after induction chemotherapy; 3. \>= 18 years 4. Patients will be recruited via the treating radiotherapist \- Exclusion Criteria: \-
References
Publications (0)
Data not yet available